208 related articles for article (PubMed ID: 26727705)
1. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
Dzieżyc K; Litwin T; Chabik G; Członkowska A
Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
[TBL] [Abstract][Full Text] [Related]
2. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
3. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
4. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
Dzieżyc K; Karliński M; Litwin T; Członkowska A
Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
[TBL] [Abstract][Full Text] [Related]
5. Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.
Vieira J; Oliveira PV; Juliano Y; Warde KR; Deguti MM; Barbosa ER; Carrilho FJ; Cancado EL
Dig Liver Dis; 2012 Apr; 44(4):323-7. PubMed ID: 22169274
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Xu SQ; Li XF; Zhu HY; Liu Y; Fang F; Chen L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):743-747. PubMed ID: 24142730
[TBL] [Abstract][Full Text] [Related]
7. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
8. [Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion].
Fukuoka N; Morita S; Hamatani S; Okada H; Kondoh M; Imai T; Ohnishi S; Itoh S
Yakugaku Zasshi; 2002 Aug; 122(8):585-8. PubMed ID: 12187774
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
Merle U; Schaefer M; Ferenci P; Stremmel W
Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
[TBL] [Abstract][Full Text] [Related]
10. Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.
Hefter H; Kuwert T; Herzog H; Arendt G; Stremmel W; Feinendegen LE
J Neurol; 1993 Nov; 241(1):49-53. PubMed ID: 8138822
[TBL] [Abstract][Full Text] [Related]
11. Wilson's disease: assessment of D-penicillamine treatment.
Van Caillie-Bertrand M; Degenhart HJ; Luijendijk I; Bouquet J; Sinaasappel M
Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
[TBL] [Abstract][Full Text] [Related]
12. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
13. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
14. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
Walshe JM
Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
[No Abstract] [Full Text] [Related]
15. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
16. [Checking of urinary copper in patients with Wilson's disease during treatment with D-penicillamine].
Indaco A; Pellegrino L; Campanella G
Acta Neurol Quad (Napoli); 1979; 39():160-4. PubMed ID: 555232
[No Abstract] [Full Text] [Related]
17. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease.
Martins da Costa C; Baldwin D; Portmann B; Lolin Y; Mowat AP; Mieli-Vergani G
Hepatology; 1992 Apr; 15(4):609-15. PubMed ID: 1551638
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of penicillamine-stimulated urinary copper excretion in the diagnosis of adult Wilson's disease.
Foruny JR; Boixeda D; López-Sanroman A; Vázquez-Sequeiros E; Villafruela M; Vázquez-Romero M; Rodríguez-Gandía M; de Argila CM; Camarero C; Milicua JM
Scand J Gastroenterol; 2008; 43(5):597-603. PubMed ID: 18415754
[TBL] [Abstract][Full Text] [Related]
19. [Late presentation of Wilson's disease].
Santander Vaquero C
Rev Esp Enferm Dig; 2002 Aug; 94(8):502-3. PubMed ID: 12486857
[No Abstract] [Full Text] [Related]
20. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
